Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > New ceo please

<< Previous

Bullboard Posts

Next >>

Comment by Transperanceon Feb 15, 2024 1:46am

111 Views

Post# 35881168

RE:RE:RE:RE:RE:New ceo please

Tyler,

We don’t know, so we can only speculate.

My speculation is that the Abbvie 1067 Right of first refusal terms gave them an advantage in the deal negotiation. If I recall it correctly, Abbvie co-financed, or perhaps even financed, the clinical study and I think Sirona had to pay more than expected for that financing later on in the 1067 deal terms.

Looking forward, there are no such Right of first refusal terms in the up-coming 1326 transaction(s). I think this was a lesson learned.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)